{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab","olaparib"]],"indication":null,"name":"NCT04666740","nct_id":"NCT04666740","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04666740. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients with either pathogenic germline or somatic alterations of 3 core homologous recombination-genes (HR-genes) - (BRCA1/2, or PALB2) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort A.","label":"Cohort A: Core HRD","type":"EXPERIMENTAL"},{"description":"Patients with either pathogenic somatic or germline non-core 14 HR-gene alterations (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort B.","label":"Cohort B: Non core HRD","type":"EXPERIMENTAL"},{"description":"Patients without any of the above HR-gene alterations included in Cohort A and B who have platinum-sensitivity, which is defined as a partial response (PR) or complete response (CR) for the best overall response (BOR) during at least 4 months on platinumbased therapy. Variants of unknown significance of candidate HR-genes from Cohort A or B will be eligible for Cohort C if they meet the partial response to platinum criterion.","label":"Cohort C: Platinum sensitive","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-01","type":"ESTIMATED"},"conditions":["Metastatic Pancreatic Ductal Adenocarcinoma","Homologous Recombination Deficiency (HRD)"],"enrollment":{"count":63,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Olaparib","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-18","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) Maintenance for Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency and/or Exceptional Treatment Response to Platinum-Based Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"6 months"}],"references":[{"citation":"Park W, O'Connor CA, Chou JF, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Homsi R, Sivaprakasam K, Umeda S, Perry MA, Varghese AM, Yu KH, Balogun F, Zervoudakis A, Katz SS, Kim TH, Zhao K, Richards AL, Lecomte N, Martin Muldoon D, Karnoub E, Chatila W, Yang J, El-Dika I, Rao D, Joshi S, Foote MB, Sugarman R, Harding JJ, Epstein AS, Kelsen D, Chalassani S, Keane F, Schoenfeld JD, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas AI, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue MT, Santos E, Rolston V, Reyngold M, Wei AC, Tipping M, Basturk O, Berger M, Kihn Do R, Schattner M, Jarnagin WR, Riaz N, Balachandran V, Pe'er D, Capanu M, Iacobuzio-Donahue C, O'Reilly EM. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nat Med. 2026 May;32(5):1783-1793. doi: 10.1038/s41591-026-04299-5. Epub 2026 Mar 25.","pmid":"41882405","type":"DERIVED"},{"citation":"Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, Sivaprakasam K, Umeda S, Perry M, Varghese A, Yu K, Balogun F, Zervoudakis A, Katz S, Kim TH, Zhao K, Richards A, Lecomte N, Muldoon D, Karnoub E, Yang J, El-Dika I, Rao D, Smita J, Foote M, Sugarman R, Harding J, Epstein A, Kelsen D, Chalasani S, Keane F, Schoenfeld J, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas A, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue M, Balachandran V, Schattner M, Santos E, Rolston V, Reyngold M, Wei A, Homsi R, Tipping M, Basturk O, Berger M, Do R, Jarnagin W, Riaz N, Pe'er D, Capanu M, Iacobuzio-Donahue C, O'Reilly E. Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial. Res Sq [Preprint]. 2025 Sep 1:rs.3.rs-7334701. doi: 10.21203/rs.3.rs-7334701/v1.","pmid":"40951294","type":"DERIVED"}],"start_date":{"date":"2020-12-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy","url":"https://clinicaltrials.gov/study/NCT04666740"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04666740"}